达格列净对2型糖尿病患者血、尿电解质及尿酸影响的病例观察  

Preliminary observation on the effect of Dapagliflozin on serum and urine electrolytes and uric acid in patients with type 2 diabetes mellitus

作　　者：刘林[1] 王薇[1] 张婷婷[1] 黄有媛[1] 陶静 高莹[1] 张俊清[1] LIU Lin;WANG Wei;ZHANG Tingting(Department of Endocrinology,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学第一医院内分泌科,100034

出　　处：《中国糖尿病杂志》2020年第5期345-349,共5页Chinese Journal of Diabetes

摘　　要：目的对T2DM患者服用达格列净(Dap)前后血、尿电解质及UA水平进行比较,评价其对T2DM的治疗作用。方法选取2018年1月至2019年10月于北京大学第一医院内分泌科门诊治疗的T2DM患者11例,在原治疗基础上每日加服Dap 10 mg,观察24周,比较用药前及用药4、12、24周时的血、尿电解质及UA变化。结果与加服Dap前比较,口服Dap 4、24周时体重[(86.5±8.8)vs(84.4±8.9)vs(85.1±13.0)kg]、24周时DBP[(82.0±5.0)vs(76.0±5.0)mmHg]、4、12、24周时血钾(K)[(4.4±0.3)vs(4.0±0.4)vs(4.0±0.4)vs(4.0±0.4)mmol/L]及4周时SUA[(380.5±70.8)vs(326.5±36.0)μmol/L]降低(P<0.05);口服Dap 12、24周时血色素[(142.0±13.0)vs(150.0±13.0)vs(152.0±15.0)g/L]及红细胞比容[(42.24±4.19)%vs(44.96±4.14)%vs(46.02±4.53)%]、12周时24 h尿镁(UMg)定量[(5.3±1.8)vs(6.4±1.8)mmol]、4周时的UA清除率[(18.7±9.4)vs(27.0±12.6)ml/min]及UA排泄分数[(7.05±1.62)%vs(9.12±1.96)%]均升高(P<0.05)。结论T2DM患者加服Dap治疗24周,体重、DBP、K、SUA降低,红细胞比容增加,UMg增多,UA清除率和排泄分数增加。Objective T2 DM patients before and after treatment with Dapagliflozin(Dap),and to evaluate its therapeutic effect on T2 DM patients.Methods pital. 10 mg Dap orally was added daily for 24 weeks,on the basis of the original treatment. The changes of the blood and urine electrolytes and UA before and after treatment were compared.Results with before Dap treatment,weight at 4 Weeks and 24 Weeks[(86. 5±8. 8)vs(84. 4±8. 9)vs(85. 1±13. 0)kg],diastolic blood pressure(DBP)at 24 Weeks[(82. 0±5. 0)vs(76. 0±5. 0)mmHg],blood potassiumat 4 Weeks,12 Weeks and 24 Weeks[(4. 4±0. 3)vs(4. 0±0. 4)vs(4. 0±0. 4)vs(4. 0±0. 4)mmol/L],SUA at 4 Weeks[(380. 5±70. 8)vs(326. 5±36. 0)μmol/L]were all significantly decreased(P<0. 05).Compared with before Dap treatment,the hemoglobin at 4 Weeks,12 Weeks and 24 Weeks[(142. 0±13. 0)vs(150. 0±13. 0)vs(152. 0±15. 0)g/L],hematocritat 12 Weeks and 24 Weeks[(42. 24±4. 19)%vs(44. 96±4. 14)% vs(46. 02±4. 53)%],the amount of 24 h urinary magnesium at 12 Weeks[(5. 3±1. 8)vs(6. 4±1. 8)mmol],the clearance rate of UA at 4 Weeks[(18. 7±9. 4)vs(27. 0±12. 6)ml/min],the uric acid excretion rate at 4 Weeks[(7. 05±1. 62)% vs(9. 12±1. 96)%]were all significantly increased(P<0. 05).ConclusionThe administrationof Dap can decrease the body weight,DBP,blood potassium and SUA,and increase the hemotocrit,24 h urinary magnesium,UA clearance rate and UA excretion fractionin T2 DM patients.

关 键 词：钠葡萄糖共转运蛋白2抑制剂 达格列净 糖尿病 2型 尿酸 血、尿电解质 

分 类 号：R587.1[医药卫生—内分泌]